← Oncology Approval Tracker

FDA DECISION ·

Jaypirca

pirtobrutinib · Eli Lilly

FDA approvalNew or expanded indicationCLL / SLL
Open LinkedIn brief ↓

1 min read · estimated

Sources

APPROVED USE

What FDA approved

Adults with previously untreated chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) with no known 17p deletion.

LAMPGEN ANALYSIS

Why it matters

This takes a noncovalent BTK inhibitor into previously untreated disease for a defined population. The comparator was bendamustine plus a rituximab product, which matters when discussing how the results fit current treatment choices.

What research teams should watch

Verify the 17p deletion result and prior-treatment history. In comparative coverage, name the exact control and distinguish continuous treatment from fixed-duration regimens.

PRIMARY RECORDS

Sources